Emerging Gene Therapy Concern: A Child Joins A Clinical Trial, But Must Be Followed Into Adulthood
Executive Summary
The long-term follow-up requirements expected for many gene therapies could raise consent and drop-out issues, which could hinder efforts to track safety and efficacy.
You may also be interested in...
US FDA Struggling With Long-Term Follow-Up Requirements For Gene Therapies
OTP Director Nicole Verdun acknowledged the agency may need help to determine how to ensure 15 years of patient follow-up is completed despite physician retirements, company closures and other issues that could impact the post-market commitments for gene therapies.
CBER Director Marks’ Intervention On Sarepta Gene Therapy Filing Decision Appears To Backfire
Former OTAT Director Wilson Bryan says Peter Marks’ order to file Sarepta’s DMD gene therapy application was mainly a public relations move, which does not seem to have worked in the FDA’s favor. Upcoming advisory committee could now involve as much scrutiny of the agency as the application itself.
CBER’s New Home For Gene Therapies: OTAT Changes To OTP But Leadership Questions Remain
US FDA has not named permanent heads of several offices within the new Office of Therapeutic Products, the only super office in the Center for Biologics Evaluation and Research.